AstraZeneca PLC
AZNNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Score 12/30
$163.95−1.46 (-0.88%)
Close on Oct 19, 2026Market cap $255.76BP/E 25.1Yield 1.91%
AstraZeneca Ultomiris (ravulizumab) by Year
Ultomiris (ravulizumab) — Emerging Markets YoY actual (%) (%)
AstraZeneca Ultomiris (ravulizumab): 84.0% in FY2025.
Latest, FY2025
84.0%
Period ended Dec 31, 2025
Change on a year earlier
–
History
2 years
Since FY2023
Sources
2
Documents cited below
Where the FY2025 figure comes from
“|| Ultomiris | 4,718 | 20 | 19 | 2,667 | 18 | 261 | 84 | 90 | 1,053 | 19 | 15 | 737 | 16 | 15”
Source: Form 6-K FY2025Q4 Earnings Release ↗
Reported in Form 6-K / 20-F Product Sales Table.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Ultomiris (ravulizumab) — Emerging Markets YoY actual (%) (%) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 84.0% | – | Form 6-K FY2025Q4 Earnings Release ↗ |
| FY2023 | Dec 31, 2023 | 88.0% | – | Form 6-K FY2023Q4 Earnings Release ↗ |
Cite this data
StockData. (2026). AstraZeneca Ultomiris (ravulizumab) (%), annual FY2023–FY2025 [Data set]. Compiled from AstraZeneca SEC filings and investor materials. https://stockdatahq.com/stocks/azn/kpis/med-ultomiris-em-act-yoy
See every metric in the AstraZeneca KPI table. Data updated Oct 28, 2026.